Bridging the gaps in paediatric visceral leishmaniasis treatment: An urgent call to action

Nirmitha L. De Silva; Manjula Hettiarachchi; Chandrika S. Ranasinghe; Thishan C. Yahathugoda; Shalindra Ranasinghe

doi:10.4103/apjtm.apjtm_348_25

Asian Pacific Journal of Tropical Medicine ›› 2025, Vol. 18 ›› Issue (11) :477 -479. DOI: 10.4103/apjtm.apjtm_348_25

Perspective

research-article

Bridging the gaps in paediatric visceral leishmaniasis treatment: An urgent call to action

Author information +

History +

PDF (189KB)

Cite this article

Download citation ▾

Nirmitha L. De Silva, Manjula Hettiarachchi, Chandrika S. Ranasinghe, Thishan C. Yahathugoda, Shalindra Ranasinghe. Bridging the gaps in paediatric visceral leishmaniasis treatment: An urgent call to action. Asian Pacific Journal of Tropical Medicine, 2025, 18 (11) : 477-479 DOI:10.4103/apjtm.apjtm_348_25

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Drugs for neglected diseases initiative (DNDi). Visceral leishmaniasis facts 2025. [Online]. Available from: https://dndi.org/diseases/visceral-leishmaniasis/facts/. [Accessed on 30 April 2024].

[2]	World Health Organisation. New framework launched to eliminate visceral leishmaniasis in eastern Africa. 2024. [Online]. Available from: https://www.who.int/news/item/12-06-2024-new-framework-launched-to-eliminate-visceral-leishmaniasis-in-eastern-africa. [Accessed on 30 June 2024].

[3]	O’Hara K. Paediatric pharmacokinetics and drug doses. Aust Prescr 2016; 39(6): 208.

[4]	De Silva NL, Hettiarachchi MH, Ranasinghe CS, Yahathugoda TC, Ranasinghe S. Therapeutic efficacy and safety of treating visceral leishmaniasis in children: A systematic review. Asian Pac J Trop Med 2025; 18(6): 243-251.

[5]	Stephenson T. How children's responses to drugs differ from adults. Br J Clin Pharmacol 2005; 59(6): 670-673.

[6]	World Health Organisation. WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia: World Health Organization; 2022. [Online]. Available from: https://www.who.int/publications/i/item/9789240048294. [Accessed on 30 June 2024].

[7]	Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, et al. Efficacy and safety of ambisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for african visceral leishmaniasis: Phase II randomised trial. PLoS Negl Trop Dis 2016; 10(9): e0004880.

[8]	Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis 2017; 11(5): e0005635.

[9]	Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, et al. Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in eastern Africa: A randomised, controlled, multicountry trial. Clin Infect Dis 2023; 76(3): e1177-e85.

[10]	World Helath Organization. Kala-Azar elimination programme: Report of a WHO consultation of partners, Geneva, Switzerland, 10-11 February 2015: World Health Organization; 2015. [Online]. Available from: https://www.who.int/publications/i/item/9789241509497. [Accessed on 30 June 2024].